Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
HeartBeam's cable-free, at-home 12-lead ECG device received FDA approval for remote arrhythmia detection.
HeartBeam, Inc. received FDA 510(k) clearance for its cable-free, at-home 12-lead ECG synthesis software, the first such device approved in the U.S. for remote arrhythmia assessment.
The credit-card-sized device captures 3D heart signals and synthesizes them into a full ECG, which is reviewed by cardiologists.
The approval follows a successful appeal of an earlier rejection and is backed by data showing high diagnostic accuracy.
The company plans a limited U.S. launch in early 2026, targeting preventive cardiology practices, with future goals including heart attack detection, an extended-wear patch, and AI-powered screening tools.
El dispositivo de ECG sin cables de HeartBeam en el hogar recibió la aprobación de la FDA para la detección remota de arritmia.